<DOC>
	<DOC>NCT00004333</DOC>
	<brief_summary>OBJECTIVES: Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type I.</brief_summary>
	<brief_title>Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Only 2 patients with tyrosinemia type I are known to this research team; others will be treated if found and if clinical conditions permit. The enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is administered orally, in 2 divided doses daily with meals. Patients will be followed closely for side effects attributable to NTBC.</detailed_description>
	<mesh_term>Tyrosinemias</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Tyrosinemia type I No cirrhosis No hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>tyrosinemia I</keyword>
</DOC>